Hybio Pharmaceutical Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Yu Pinxiang
Chief executive officer
CN¥1.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.6yrs |
| CEO ownership | 0.06% |
| Management average tenure | 3.2yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 26% Price Boost Is Out Of Tune With Revenues
Dec 20
Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking
Sep 30Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt
Jul 20Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues
Jun 03Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up
Feb 29Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?
Feb 26CEO
Yu Pinxiang (51 yo)
5.6yrs
Tenure
CN¥1,842,600
Compensation
Ms. Pinxiang Yu serves as Director of Hybio Pharmaceutical Co., Ltd. since May 31, 2019 and serves as its Executive President. She served as a Vice President of Production Department at Hybio Pharmaceutica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive President & Director | no data | CN¥1.84m | 0.060% CN¥ 6.8m | |
| VP, CFO & Accounting Supervisor | 3.4yrs | CN¥649.80k | no data | |
| VP, Secretary & Director | 2.9yrs | CN¥781.00k | no data | |
| Vice President | 3.3yrs | CN¥1.19m | no data | |
| Vice President | 3yrs | CN¥616.50k | no data | |
| Vice President of Human Resource & Administration Department | no data | CN¥840.50k | no data | |
| Vice President of Marketing | no data | CN¥398.30k | no data |
3.2yrs
Average Tenure
48yo
Average Age
Experienced Management: 300199's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive President & Director | 5.6yrs | CN¥1.84m | 0.060% CN¥ 6.8m | |
| VP, Secretary & Director | 4.7yrs | CN¥781.00k | no data | |
| Independent Director | 3.3yrs | CN¥60.00k | no data | |
| Non-Independent Director | 4.9yrs | CN¥65.70k | 2.46% CN¥ 279.9m | |
| Member of Non-Employee Supervisory Board | 3yrs | no data | no data | |
| Chairman of Supervisory Board | 5.6yrs | no data | no data | |
| VP & Director | 3.9yrs | CN¥976.90k | no data | |
| Independent Director | 3yrs | CN¥120.00k | no data | |
| Vice Chairman | 15.1yrs | CN¥60.10k | 8.15% CN¥ 927.9m | |
| Chairman | 15.1yrs | CN¥1.12m | 12.41% CN¥ 1.4b | |
| Supervisor | no data | no data | no data |
4.8yrs
Average Tenure
48yo
Average Age
Experienced Board: 300199's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 17:16 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hybio Pharmaceutical Co., Ltd. is covered by 19 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhouyu Deng | BOCI Research Ltd. |
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |